IM-92

N/A

Report date: 2025/07/26 20:00:09

Base Information

Drug NameIM-92

Drug Alias NameIM-92

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacements

TargetsClaudin-18 splice variant 2

Therapy Area/IndicationsPancreatic NeoplasmsStomach NeoplasmsEsophageal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaPending

Originator CompaniesImunopharm Technology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesImunopharm Technology Co Ltd

Active IndicationsN/A

Inactive IndicationsPancreatic NeoplasmsStomach NeoplasmsEsophageal Neoplasms

Other Information

ATC CodeN/A